G protein–coupled receptor 21 in macrophages: An in vitro study

• Published in: European journal of pharmacology 2022-07, Vol.926, p.175018-175018, Article 175018
• Main Authors: Bordano, Valentina, Kinsella, Gemma K., Cannito, Stefania, Dianzani, Chiara, Gigliotti, Casimiro Luca, Stephens, John C., Monge, Chiara, Bocca, Claudia, Rosa, Arianna C., Miglio, Gianluca, Dianzani, Umberto, Findlay, John B.C., Benetti, Elisa
• Format: Article
• Language: English
• Subjects: GPCR receptors; GPR21; Inflammation; Macrophages
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2022.175018

GPR21 is an orphan and constitutively active receptor belonging to the superfamily of G-Protein Coupled Receptors (GPCRs). GPR21 couples to the Gq family of G proteins and is expressed in macrophages. Studies of GPR21 knock-out mice indicated that GPR21 may be involved in promoting macrophage migration. The aim of this study was to evaluate the role of GPR21 in human macrophages, analyzing (i) its involvement in cell migration and cytokine release and (ii) the consequence of its pharmacological inhibition by using the inverse agonist GRA2. THP-1 cells were activated and differentiated into either M1 or M2 macrophages. GPR21 expression was evaluated at gene and protein level, the signalling pathway was investigated by an IP1 assay, and cytokine release by ELISA. Cell migration was detected by the Boyden chamber migration assay, performed on macrophages derived from both the THP-1 cell line and human peripheral blood monocytes. In addition, we compared the effect of the pharmacological inhibition of GPR21 with the effect of the treatment with a specific GPR21 siRNA to downregulate the receptor expression, thus confirming that GRA2 acts as an inverse agonist of GPR21. GRA2 does not affect cell viability at the tested concentrations, but significantly reduces the release of TNF-α and IL-1β from M1 macrophages. The analysis of the migratory ability highlighted opposite effects of GRA2 on M1 and M2 macrophages since it decreased M1, while it promoted M2 cell migration. Therefore, the pharmacological inhibition of GPR21 could be of interest for pathological conditions characterized by low grade chronic inflammation. [Display omitted] •GPR21 expression is higher in M1 over M2 macrophages derived from THP-1 cells.•A GPR21 inverse agonist, GRA2, reduces proinflammatory cytokine release.•GPR21 inhibition decreases migration of M1 macrophages but induces that of M2 cells.•GPR21 inhibition might reduce inflammation by modulating macrophage behaviour.